Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Feasibility Study of Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

NCT06485076 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06485076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06485076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Feasibility Study of Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Lead sponsor
University Health Network, Toronto
Phase
Not applicable
Overall status
Recruiting
Start date
July 18, 2024
Completion date
June 30, 2027
Enrollment
144 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive lymphoma, b cell lymphoma, lymphoma, b-cell, multiple myeloma, multiple myeloma in relapse, multiple myeloma progression, multiple myeloma stage iii, multiple myeloma, refractory